Showing results (11-20 of 764) with videos related to

Sort By:
Pageof 77
Expert Opinion on Investigational Drugs|December 5, 2008
Milatuzumab: a promising new agent for the treatment of lymphoid malignanciesTomer Mark, Peter Martin, John P Leonard, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 4, 2021
Worsening Quality of Life in Indolent Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia Patients in Active Surveillance: A 12-Month Longitudinal StudyKelly M Trevino, Peter Martin, Zhengming Chen, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 21, 2022
Age Differences in Clinical Trial Understanding in Non-Hodgkin Lymphoma PatientsDanny Luan, Peter Martin, John P Leonard, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 19, 2007
Phase I to III trials of anti-B cell therapy in non-Hodgkin's lymphomaPeter Martin, Richard R Furman, Morton Coleman, et al.
Leukemia & Lymphoma|June 4, 2021
Unmet need for mental health services in indolent lymphoma: age differences over one-year post-diagnosisKelly M Trevino, Peter Martin, Rebecca Saracino, et al.
Clinical Lymphoma & Myeloma|June 16, 2009
Durable complete remissions in HIV-associated Hodgkin lymphoma after treatment with only one cycle of chemotherapy complicated by sepsisPeter Martin, John P Leonard, Morton Coleman, et al.
Hematology (Amsterdam, Netherlands)|April 18, 2012
Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimenMorton Coleman, Gia Ruan, Rebecca L Elstrom, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 15, 2019
Lymphoma Study Titles on ClinicalTrials.gov Lack Details Necessary for Study IdentificationAhmed Toure, Paola Ghione, Samantha Phillips, et al.
British Journal of Haematology|July 6, 2017
Bone marrow biopsies do not impact response assessment for follicular lymphoma patients treated on clinical trialsSarah C Rutherford, Valery Li, Paola Ghione, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 27, 2021
An Assessment of Race as a Risk Factor for Doxorubicin-Related Cardiotoxicity in Diffuse Large B-Cell LymphomaAhmed Toure, Danny Luan, Yiyuan Wu, et al.
Pageof 77